Soleus Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $34.8M | Buy |
+106,750
| New | +$34.8M | 2.31% | 12 |
|
|
2025
Q1 | – | Sell |
-76,800
| Closed | -$18.1M | – | 75 |
|
|
2024
Q4 | $18.1M | Buy |
76,800
+17,400
| +29% | +$4.09M | 1.14% | 26 |
|
|
2024
Q3 | $16.3M | Sell |
59,400
-12,300
| -17% | -$3.38M | 1.27% | 28 |
|
|
2024
Q2 | $17.4M | Buy |
+71,700
| New | +$17.4M | 1.54% | 25 |
|
|
2023
Q4 | – | Sell |
-3,900
| Closed | -$691K | – | 76 |
|
|
2023
Q3 | $691K | Buy |
+3,900
| New | +$691K | 0.06% | 83 |
|
|
2022
Q4 | – | Sell |
-27,000
| Closed | -$5.4M | – | 74 |
|
|
2022
Q3 | $5.4M | Buy |
27,000
+6,900
| +34% | +$1.38M | 0.73% | 40 |
|
|
2022
Q2 | $2.93M | Buy |
+20,100
| New | +$2.93M | 0.46% | 55 |
|